TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that co-founder and CEO Adi Mor, PhD, will participate in Oppenheimer's Movers in Rare Disease Summit on Thursday, December 11, 2025, at the Sofitel Hotel in New York City. The invitation-only Rare Disease Summit will feature a day of panels, presentations and 1 ...

—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a Clinical Event Composite Endpoint— —Phase 2 SPRING Trial OLE Data Showing Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks Presented at AASLD 2025— —New Clinical Data Presented at AASLD 2025 Provides Insights on Nebokitug’s Direct Macrophage-Med ...

— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks— —New Clinical Data Provides Insights on Nebokitug’s Direct Macrophage-Mediated Mechanisms that Are Key to PSC Disease Progression— —All Three Presentations Have Been Designated as Posters of Distinction— TEL AVIV, Israel and WASHINGTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical sta ...

Core Insights - Three stocks are highlighted with strong momentum characteristics and a buy rank as of October 23, including Par Pacific Holdings, Chemomab Therapeutics, and Guess, Inc. [1][2][3] Group 1: Par Pacific Holdings, Inc. (PARR) - Par Pacific Holdings has a Zacks Rank 1 and saw its earnings estimate increase by 100.6% over the last 60 days [1] - The company's shares increased by 17.5% over the last three months, outperforming the S&P 500, which advanced by 6% [1] - Par Pacific possesses a Momentum Score of A [1] Group 2: Chemomab Therapeutics Ltd. (CMMB) - Chemomab Therapeutics also holds a Zacks Rank 1, with a 70% increase in its earnings estimate over the last 60 days [2] - The stock gained 18.9% in the last month, significantly outperforming the S&P 500's 1.7% increase [2] - Chemomab has a Momentum Score of A [2] Group 3: Guess?, Inc. (GES) - Guess has a Zacks Rank 1, with an 8.1% increase in its earnings estimate over the last 60 days [3] - The company's shares rose by 27.4% over the last three months, again outperforming the S&P 500's 6% advance [3] - Guess possesses a Momentum Score of B [3]

Core Insights - Biotech stocks experienced significant gains in after-hours trading on October 22, 2023, primarily driven by Ventyx Biosciences' positive Phase 2 data, which led to an 88% surge in its stock price [1][2]. Company Performance - Ventyx Biosciences Inc. (VTYX) saw its shares increase by over 88% following the announcement of positive results from its Phase 2 study of VTX3232 for patients with obesity and cardiovascular risk factors [2]. - Medpace Holdings, Inc. (MEDP) reported better-than-expected Q3 results, resulting in an over 18% increase in its stock price during after-hours trading [2]. - Inhibrx Biosciences Inc. (INBX) shares rose over 10% to $34.98 after announcing a live webcast presentation to discuss topline results from the ChonDRAgon study [3]. - SCYNEXIS Inc. (SCYX) shares increased by over 11% to $0.87 [4]. - Acumen Pharmaceuticals Inc. (ABOS) experienced a notable rise of over 24.9% to $2.31 [4]. - Rani Therapeutics Holdings Inc. (RANI) shares were up over 9% at $2.64 [4]. - iBio Inc. (IBIO) shares increased by over 7% to $1.50 [4]. - Chemomab Therapeutics Ltd. (CMMB) shares rose over 7% to $3.32 [4]. - Nautilus Biotechnology Inc. (NAUT) shares increased by over 7% to $1.35 [4]. - ProQR Therapeutics N.V. (PRQR) shares were up over 7% at $2.92 [4]. - Tyra Biosciences Inc. (TYRA) shares increased by over 7% to $15.00 [4]. - Imunon Inc. (IMNN) shares rose over 4% to $4.90 [4].

Summary of Chemomab Therapeutics (CMMB) FY Conference Company Overview - **Company**: Chemomab Therapeutics - **Focus**: Development of novel treatments for inflammatory and fibrotic diseases - **Lead Asset**: First-in-class monoclonal antibody targeting CCL24, involved in inflammation and fibrosis [2][4] Industry Context - **Target Disease**: Primary sclerosing cholangitis (PSC) - **Characteristics**: Significant inflammation and fibrosis in the bile duct, no approved treatments available [3][5] - **Patient Demographics**: Approximately 70,000 patients in major markets, primarily young men around their 40s [6] Clinical Development - **Phase II Study**: Successfully completed with positive results - **Participants**: 76 patients, treated with Nebucadnezar at doses of 10 mg/kg, 20 mg/kg, and placebo [9] - **Endpoints**: Safety, tolerability, and various markers of disease progression [10] - **Results**: - Met primary safety endpoint and secondary endpoints showing anti-inflammatory and anti-fibrotic activity [11] - Identified 20 mg/kg as the effective dose for further studies [11] Efficacy and Safety Data - **Biomarker Improvements**: - Significant reduction in liver stiffness and ELF score, indicating disease progression [12][13] - Dose-dependent improvements in inflammatory markers such as IL-6 and IL-18 [14] - **Long-term Safety**: - 93% of eligible patients continued in open-label extension, showing sustained reduction in biomarkers after 48 weeks [16] - Nebucadnezar remained safe and well-tolerated [16] Competitive Landscape - **Unique Positioning**: - Nebucadnezar is the only drug suggesting disease modification in PSC, unlike competitors focusing on symptom management [6][7] - Potential to become the first approved drug for PSC, addressing a significant unmet medical need [8] Market Opportunity - **Commercial Potential**: - Estimated annual commercial opportunity exceeding $1 billion under conservative assumptions [9] - Premium pricing expected due to first-in-class mechanism and significant unmet need [9] Regulatory Engagement - **FDA Interaction**: - Clear alignment with FDA on a single pivotal study for full approval of Nebucadnezar in PSC [20][21] - Study design will evaluate multiple clinical events beyond just liver transplant and death [21] Future Plans - **Phase III Study**: - Preparations underway to initiate Phase III clinical study as soon as possible [22] - Ongoing discussions with potential partners to facilitate market entry [22] Conclusion - **Transformative Potential**: - Nebucadnezar represents a breakthrough in PSC and potentially other fibrotic diseases, with strong data supporting its efficacy [23] - Chemomab Therapeutics is positioned to lead in addressing this rare disease with significant unmet needs [23]

Core Insights - Chemomab Therapeutics Ltd. is a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet need [3] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference, with a prerecorded presentation available starting September 5, 2025 [1][2] Company Overview - Chemomab is developing nebokitug (CM-101), a first-in-class dual activity monoclonal antibody targeting the soluble protein CCL24, which plays a role in fibrosis and inflammation [3] - Nebokitug has shown disease-modifying potential and a favorable safety profile in clinical and preclinical studies, indicating its potential to treat severe fibro-inflammatory diseases [3] - The company has reported positive results from five clinical trials of nebokitug, particularly from the Phase 2 SPRING trial in primary sclerosing cholangitis (PSC) [3] - Chemomab is preparing for a potential Phase 3 trial in PSC, which will be a single pivotal trial with a clinical event primary endpoint, aiming for full regulatory approval [3] - Nebokitug has received Orphan Drug designation from the FDA and EMA, as well as Fast Track designation from the FDA for the treatment of PSC [3] - The program for treating systemic sclerosis with nebokitug has an open U.S. IND [3]

Core Insights - Catholic Medical Mission Board (CMMB) is launching an emergency response in South Sudan due to a cholera outbreak and a deepening hunger crisis affecting thousands of lives in Upper Nile and Central Equatoria State [1] - The cholera outbreak has infected over 85,700 individuals, primarily children under 14, with case fatality rates exceeding WHO emergency thresholds [1] Group 1: Emergency Response - CMMB is distributing P&G Purifier of Water sachets to families in the most affected areas to curb the cholera spread [2] - The partnership with P&G has been crucial in enabling CMMB to respond quickly to the crisis [2] - Additional resources are urgently needed to address the complex health threats faced by the population [3] Group 2: Collaborative Efforts - CMMB supports a consortium of local and international actors to implement a multisectoral response to the emergency [4] - The organization is involved in supporting oral cholera vaccination campaigns led by the Ministry of Health, with logistical support from UNICEF and WHO [7] - CMMB is running mobile clinics to provide treatment for childhood illnesses and nutrition services for displaced populations [7] Group 3: Call to Action - CMMB has launched an emergency campaign to expand its lifesaving response, emphasizing the urgency of contributions to prevent further deaths [5] - The organization has a long history of providing medical and development aid, focusing on women's and children's health in various countries [6] - In 2024, CMMB's Access to Medicines program delivered $278.9 million worth of medicines and medical supplies to 32 countries [6]

Exhibit 99.1 Chemomab Therapeutics Ltd. and its subsidiaries Interim Condensed Consolidated Financial Statements As of June 30, 2025 (Unaudited) Chemomab Therapeutics Ltd. and its subsidiaries Interim Condensed Consolidated Financial Statements as of June 30, 2025 (Unaudited) (*) 1 American Depositary Share (ADS) represents 20 Ordinary Shares 3 Contents | | Page | | --- | --- | | Interim Condensed Consolidated Balance Sheets | 3 | | Interim Condensed Consolidated Statements of Operations | 4 | | Interim Con ...

Core Insights - Chemomab Therapeutics is advancing its Phase 3 program for nebokitug, a treatment for primary sclerosing cholangitis (PSC), and is actively seeking strategic partnerships to optimize development resources and accelerate the program [3][4][11] - The company has received positive feedback from the FDA regarding the Chemistry, Manufacturing, and Controls (CMC) strategy and the timeline for nonclinical toxicology testing, which supports the timely advancement of the Phase 3 program [7][11] - Chemomab plans to adjust the ratio of its American Depositary Shares (ADSs) from 1:20 to 1:80, effective August 26, 2025, which will serve as a reverse split for ADS holders [3][10] Company Developments - The Phase 2 SPRING trial data for nebokitug was presented at major scientific meetings, highlighting its anti-fibrotic, anti-inflammatory, and anti-cholestatic effects [2][4][5] - Chemomab has expanded its patent protections for nebokitug in China and Russia, extending coverage until 2041, which is crucial for future commercialization [7][9] - The company reported a net loss of $2.1 million for Q2 2025, a decrease from $3.6 million in Q2 2024, reflecting reduced R&D expenses due to the completion of the Phase 2 trial [6][15] Financial Highlights - As of June 30, 2025, Chemomab had cash and cash equivalents of $9.5 million, expected to fund operations through the second quarter of 2026 [6][10] - R&D expenses for Q2 2025 were $1.3 million, down from $2.9 million in Q2 2024, while G&A expenses increased to approximately $1.0 million from $0.8 million in the same period [6][15] - The total number of ordinary shares issued and outstanding increased to 413,851,140 as of June 30, 2025, compared to 377,132,220 as of December 31, 2024 [10][14]